Oncochip Technology Could Increase Cancer Sample Tests by Up to 50 Times

Innovative Technology Oncochip Technology Could Increase Cancer Sample Tests by Up to 50 Times

2025-07-16 Source: Press release Amsbio 1 min Reading Time

Related Vendor

A new screening tool has been developed by researchers which has the potential to increase the number of tests on a solid tumor sample by up to 50 times. The tool is specifically designed for testing at scale the latest immunotherapies.

The Onco-Chip3D Single platform (Screenin3D) enables a variety of miniaturized in vitro assays to be performed with physiologically relevant 3D co-culture tumor models.(Source: Amsbio) — The Onco-Chip3D Single platform (Screenin3D) enables a variety of miniaturized in vitro assays to be performed with physiologically relevant 3D co-culture tumor models.
(Source: Amsbio)

A screening tool developed in research led at the University of Strathclyde, UK could increase the number of tests on a solid tumor sample by up to 50 times. The tool is designed for testing at scale the latest immunotherapies, such as Chimeric Antigen Receptor (Car) T-cell therapy, which is effective against many haematological cancers but presents challenges when used to treat solid tumors. Traditional 2D models that are currently used fail to reproduce the complexity of the tumor’s microenvironment, while models based on patients’ tumors are costly and labor-intensive.

The Strathclyde-led study has developed a miniaturized platform for screening 3D tumor models to evaluate the toxicity of Car-T therapy towards cells. The platform enabled visualization and quantification of how Car-T cells rapidly targeted, broke up and killed cancer cells without causing significant harm to other cells.

In addition, the research found that, while chemotherapy treatment did not act specifically on cancer cells when used alone, cancer cell specificity was enhanced when combined with Cat-T cell treatment.

The study also involved researchers at the University of Glasgow and the Cancer Research UK Beatson Institute in Glasgow. This groundbreaking work has been published in the IEEE Open Journal of Engineering in Medicine and Biology. The research was led by Dr. Michele Zagnoni, a Reader in Strathclyde’s Department of Electronic and Electrical Engineering, and recently graduated PhD student Karla Paterson.

The technology is to be commercialized by Screenin3D, a pre-spinout company co-founded in 2018 by Dr. Zagnoni, who is the company’s CEO, and Alex Sim, who is its Executive Chair.

(ID:50485392)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Business E-mail

Please enter a valid mailadress.

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Date: 08.12.2025

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.